| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,200 | 6,500 | 15:42 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 11,000 | 500 | |||
| 9,500 | 175 | |||
| 8,550 | 450 | |||
| 8,000 | 41 | |||
| 6,500 | 788 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 788 | 6,200 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.849 | 0,740 | 2.108 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 30.09.2026 | 12:23:22 | 6,450 | 71 |
| Tagesumsatz Xetra | +0,050 +0,79 % | 83 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | 4basebio meldet starken Anstieg der Auftragseingänge bei sinkendem Umsatz | 33 | Investing.com Deutsch | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Mo | 4basebio reports 210% rise in H1 sales orders amid revenue decline | 11 | Investing.com | ||
| Mo | 4basebio PLC H1 Loss Rises | 6 | RTTNews | ||
| Mo | 4BASEBIO PLC: 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program | 9 | Cision News | ||
| 07.09. | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 694 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:30 | GOLDMAN SACHS stuft Sartorius Stedim Biotech auf 'Buy' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Sartorius Stedim von 208 auf 223 Euro angehoben und die Einstufung auf "Buy" belassen. Die Erholung im Bereich... ► Artikel lesen | |
| 13:06 | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | GlobeNewswire (Europe) | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| 14:06 | Evommune, Inc.: Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress | Business Wire | Presentation highlights EVO301's clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitisBiomarker... ► Artikel lesen | |
| 13:06 | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | GlobeNewswire (Europe) | Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating... ► Artikel lesen | |
| 13:06 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | GlobeNewswire (Europe) | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen |